Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry

Volition study shows rapid, low-cost, automated Nu.Q® Cancer test accurately detects human cancers at high specificityHENDERSON, Nev., March 21, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer immunoassay test in development detected a range of 21 different cancers. This could potentially be used as a standalone pan-cancer test or, given its low false positive r ...